Allergan Plc

Allergan Plc

Allergan Plc

Overview
Date Founded

1982

Headquarters

Clonshaugh Business & Tech. Park,Coolock,Dublin D17 E400

Type of Company

Public

Employees (Worldwide)

31.2K

Industries

Pharmaceuticals

Company Description

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.

Contact Data
Trying to get in touch with decision makers at Allergan Plc? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Executive Vice President & Chief Financial Officer

Senior Vice President & Chief Financial Officer

Executive Vice President

Executive Vice President & President-International Brands

Board of Directors

Chief Financial Officer & Executive Vice President at AbbVie, Inc.

Finance Director at AbbVie, Inc.

Director at Allergan Plc

Director at Allergan Plc

Director at Allergan Plc

Paths to Allergan Plc
Potential Connections via
Relationship Science
You
Allergan Plc
Owners & Shareholders
Details Hidden

Columbus Hill Capital Management seeks to achieve attractive returns over a multi-year period through all phases of the market cycle by applying a multi-disciplinary approach to investing and maintaining a focus on capital preservation. They strive to achieve their investment objectives by utilizing the following strategies: (1) high-yield bonds, stressed and defaulted debt and equity securities, post-reorganization equity securities, bank loans (including first lien, second lien and debtor-in-possession bank loans), credit default swaps and other debt and equity securities, including sovereign debt securities; (2) event-driven investments, such as investments made as a result of third party litigations, corporate reorganizations, bankruptcies, and mergers and acquisitions; and (3) investments in private companies and special situations investments. Columbus Hill may invest worldwide in U.S. and non-U.S. securities and other instruments, including: (1) equities (listed, unlisted, traded or privately offered, domestic, foreign, American depository receipts and preferred); (2) secured and unsecured debt (both corporate and sovereign, bank loans, and other legal and/or contractual claims); (3) convertible bonds and preferred stock; and (4) derivative instruments, including listed and over-the-counter options, futures, forward contracts, swaps, caps, floors, and other equity and fixed income related instruments, and contracts for differences.

Details Hidden

Columbus Hill Capital Management seeks to achieve attractive returns over a multi-year period through all phases of the market cycle by applying a multi-disciplinary approach to investing and maintaining a focus on capital preservation. They strive to achieve their investment objectives by utilizing the following strategies: (1) high-yield bonds, stressed and defaulted debt and equity securities, post-reorganization equity securities, bank loans (including first lien, second lien and debtor-in-possession bank loans), credit default swaps and other debt and equity securities, including sovereign debt securities; (2) event-driven investments, such as investments made as a result of third party litigations, corporate reorganizations, bankruptcies, and mergers and acquisitions; and (3) investments in private companies and special situations investments. Columbus Hill may invest worldwide in U.S. and non-U.S. securities and other instruments, including: (1) equities (listed, unlisted, traded or privately offered, domestic, foreign, American depository receipts and preferred); (2) secured and unsecured debt (both corporate and sovereign, bank loans, and other legal and/or contractual claims); (3) convertible bonds and preferred stock; and (4) derivative instruments, including listed and over-the-counter options, futures, forward contracts, swaps, caps, floors, and other equity and fixed income related instruments, and contracts for differences.

Recent Transactions
Details Hidden

Nestlé SA purchases Allergan Plc /Zenpep Business from Allergan Plc

Details Hidden

AbbVie, Inc. purchases Allergan Plc

Details Hidden

Allergan Plc purchases Envy Medical, Inc. from HCP & Co.

Transaction Advisors
Legal Advisor

Advised onAllergan Plc purchases Allergan, Inc.

Legal Advisor

Advised onAbbVie, Inc. purchases Allergan Plc

Legal Advisor

Advised onAllergan Plc purchases Zeltiq Aesthetics, Inc.

Legal Advisor

Advised onAllergan Plc purchases Zeltiq Aesthetics, Inc.

Legal Advisor

Advised onAllergan Plc purchases Zeltiq Aesthetics, Inc.

Legal Advisor

Advised onAllergan Plc purchases Zeltiq Aesthetics, Inc.

Advisors & Consultants
Consultant

Former Senior Vice President, Finance & Treasurer at PepsiCo, Inc.

Legal Advisor

US Chair, Life Sciences Patent Litigation Practice at DLA Piper

Legal Advisor

Partner at Wachtell, Lipton, Rosen & Katz

Clients

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AmerisourceBergen Corp. engages provision of pharmaceutical products and business solutions that improve access to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical Distribution Services segment distributes a comprehensive offering of brand-name, specialty brand-name & generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies & equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent & chain retail pharmacies, mail order pharmacies, medical clinics, long-term care & alternate site pharmacies, and other customers. The Other segment focuses on global commercialization services and animal health and includes ABCS, World Courier, and MWI. The company is headquartered in Chesterbrook, PA.

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The company operates through the following segments: Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes cardinal health branded medical, surgical and laboratory products. The company was founded by Robert D. Walter in 1971 and is headquartered in Dublin, OH.

Key Stats and Financials As of
Market Capitalization
$61.8B
Total Enterprise Value
Earnings Per Share
Investors
Details Hidden

Chief Executive Officer at Innocrin Pharmaceuticals, Inc.

Details Hidden

Co-Founder at Longitude Capital Management Co. LLC

Details Hidden

Investor at Neuronetics, Inc.

Suppliers
The Chemical Works of Gedeon Richter Plc Pharmaceuticals | Budapest, Hungary

The Chemical Works of Gedeon Richter Plc engages in the development and manufacture of pharmaceuticals. It operates through the following segments: Pharmaceuticals, Wholesale and Retail, and Others. The Pharmaceutical segment engages in research and development, manufacturing, sales and marketing of pharmaceutical products. The Wholesale and Retail segment represents the distribution chain in the market which facilitate the product reaching the final buyers. The Other segment relates to the business of the members of the group that do not belong to any of the segments. The company was founded by Gedeon Richter in 1901 and is headquartered in Budapest, Hungary.

Savient Pharmaceuticals, Inc. Biotechnology | Bridgewater, NJ

Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ.

Merck & Co., Inc. Medical Support Services | Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Competitors
Novartis AG Pharmaceuticals - Basel, Switzerland

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Allergan Plc. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Allergan Plc's profile does not indicate a business or promotional relationship of any kind between RelSci and Allergan Plc.